Amylyx is an IND-enabling stage pharmaceutical company dedicated to providing innovative, disease-modifying solutions to neurodegenerative diseases.
Amylyx Pharmaceutical Corp.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
Oct 2017, The Alzheimers Association and Alzheimers Drug Discovery Foundation fund Amylyx Pharmaceuticals $1.85 million grant to support a phase 2 clinical trial of AMX0035.
Aug 2016, Amylyx completed a $5 million Series A financing led by Morningside Venture, ALS Investment Fund and former Genzyme CEO Henri Termeer as well as new and previous private investors.
In Jul 2016, Amylyx recieved $2.96 Mn grant from the ALS Association and ALS Finding a Cure, to fund Ph II trial for AMX0035. Earlier in 2015, company raised $1.3 Mn and $600,000 from the ALS Finding a Cure Foundation and the Cure Alzheimers Fund.